Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways Ebglyss is now positioned to move from province‑specific coverage into broad, pan-Canadian reimbursement, which should materially expand Lilly’s eczema market and patient access. ...
Takeaways: Cipher’s pCPA LOI for Epuris is a market inflection point that should expand revenue and prescription volume by shifting isotretinoin from patchy, private-pay cove...
Takeaways: The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, w...
